A Randomized, Double-blind, Placebo-controlled study to evaluate the long-term safety and efficacy of Darbepoetin alfa administered at 500 ug once every 3 weeks in anemic subjects with advanced NSCLC receiving multi-cy

Grants and Contracts Details

StatusFinished
Effective start/end date2/26/10 → 12/31/12

Funding

  • AMGen: $5,000.00